Xamoterol, a partial b 1 -adrenergic receptor agonist, has been reported to impair the retrieval of hippocampus-dependent spatial reference memory in rats. In contrast, xamoterol restores memory retrieval in gene-targeted mice lacking norepinephrine (NE) and in a transgenic mouse model of Down syndrome in which NE levels are reduced. Restoration of retrieval by xamoterol in these two models complements the observation that NE and b 1 signaling are required for hippocampusdependent retrieval of contextual and spatial reference memory in wild-type mice and rats. Additional evidence indicates that cAMP-mediated PKA and Epac signaling are required for the retrieval of hippocampus-dependent memory. As a result, we hypothesized that xamoterol has effects in addition to the stimulation of b 1 receptors that, at higher doses, act to counter the effects of b 1 signaling. Here we report that xamoterol-induced disruption of memory retrieval depends on b 2 -adrenergic receptor signaling. Interestingly, the impairment of memory retrieval by xamoterol is blocked by pretreatment with pertussis toxin, an uncoupling agent for G i/o signaling, suggesting that b 2 signaling opposes b 1 signaling during memory retrieval at the level of G protein and cAMP signaling. Finally, similar to the time-dependent roles for NE, b 1 , and cAMP signaling in hippocampus-dependent memory retrieval, xamoterol only impairs retrieval for several days after training, indicating that its effects are also limited by the age of the memory. We conclude that the disruption of memory retrieval by xamoterol is mediated by G i/o -coupled b 2 signaling, which opposes the G s -coupled b 1 signaling that is transiently required for hippocampus-dependent emotional memory retrieval.
Among the neural systems that underlie episodic memory, the hippocampus is central. Bilateral damage to the hippocampus eliminates the ability to form new episodic memories, as well as impairs the ability to recall recent but not remote episodic memories (McClelland et al. 1995; Squire et al. 2001) . Intense, psychologically traumatic experiences can lead to psychiatric problems such as post-traumatic stress disorder (PTSD). Dysregulation of episodic memory is one of the cardinal symptoms in PTSD patients, who often suffer from recurrent, intrusive memories of traumatic events (Rubin et al. 2008) . Frequent retrieval of such memories can be debilitating due to the fear and anxiety they invoke.
For this and other reasons, the mechanisms underlying the consolidation, retrieval and, reconsolidation of episodic memory are of great interest. Many studies have contributed to our understanding of the molecular and cellular signaling pathways important for episodic memory consolidation (Kandel 2001; Morris et al. 2003; Tonegawa et al. 2003; Abel and Nguyen 2008) . In addition, some studies have begun to illuminate signaling pathways required for the retrieval of episodic memory (Szapiro et al. 2002; Martin and Clark 2007) . As a result, it has been suggested that the consolidation and retrieval of hippocampus-dependent memory have common neurobiologic substrates and signal transduction pathways. As an example, nearly four decades of research across species illustrate that agents that acutely elevate cAMP (cyclic 3 ′ ,5 ′ -adenosine monophosphate) usually enhance memory consolidation, whereas agents that block cAMP signaling impair consolidation (Kandel 2001; Abel and Nguyen 2008) .
Recent evidence suggests that cAMP signaling is also involved in hippocampus-dependent memory retrieval. Bilateral infusion of a cAMP antagonist into the dorsal hippocampus (DH) of rats 10 min before testing inhibitory avoidance 1 d after training reduces step-down latency (Barros et al. 2000) . Further, signaling by norepinephrine (NE) through the b 1 -adrenergic receptor is required for the retrieval of an intermediate phase (from 2 h to 4 d after training) of hippocampus-dependent memory (Murchison et al. 2004) . Mice with targeted disruption of the gene for the b 1 receptor (b 1 KO) display deficits in contextual fear, and systemic administration of the b 1 antagonist betaxolol produces retrieval deficits in wild-type mice and rats. These effects are reproduced by infusion of the b 1 -selective antagonist atenolol into the DH.
b 1 receptors couple to the adenylyl cyclase stimulatory G protein, G s , and their activation elevates cAMP levels in the DH (Fowler and O'Donnell 1988) . cAMP antagonists impair retrieval when infused into the DH shortly before testing contextual fear, and DH infusion of cAMP agonists rescues retrieval in genetargeted mice lacking NE (Ouyang et al. 2008) . Further, activation of at least two targets of cAMP signaling, protein kinase A (PKA) and the exchange protein activated by cAMP (Epac), is also required for hippocampus-dependent memory retrieval. Finally, transgenic mice expressing an invertebrate, G s -coupled octopamine receptor exhibit both octopamine-dependent increases in DH cAMP and enhanced contextual fear memory retrieval (Isiegas et al. 2008) .
In contrast to the above, it has been suggested that stimulation of b 1 receptors impairs hippocampus-dependent memory retrieval. In rats, DH infusion of the b 1 -selective antagonist atenolol blocks the impairing effects of a glucocorticoid receptor agonist on the retrieval of spatial reference memory (Roozendaal et al. 2004 ). Similar to a glucocorticoid agonist, injection of 3 or 10 mg/kg of the b 1 -selective agonist xamoterol decreases spatial reference memory retrieval. The authors conclude that the impairment of memory retrieval by glucocorticoids and xamoterol involves the activation of b 1 -coupled cAMP signaling in the hippocampus. This observation is surprising because administration of xamoterol at 1 -3 mg/kg fully rescues contextual memory retrieval in gene-targeted NE-deficient mice, suggesting that b 1 signaling is sufficient for the role of NE in retrieval (Murchison et al. 2004) .
The goal of this study was to resolve the seemingly conflicting observations that b 1 signaling is required for hippocampusdependent memory retrieval and is also responsible for the impairment of retrieval. Of note, somewhat higher doses of xamoterol were needed to impair retrieval in wild-type rats as compared to those needed to rescue retrieval in mutant mice. Differences in dosing requirements could be due to differences between species, genetic manipulation, or mechanism of action. To address this, we first confirmed that xamoterol impairs memory retrieval in wild-type mice, making a difference between species unlikely. As a result, we hypothesized that the pharmacologic characterization of xamoterol-induced retrieval impairment was incomplete and that another adrenergic receptor might mediate this effect. We considered the b 2 receptor as a potential target of xamoterol because this receptor is most closely related to the b 1 receptor pharmacologically, and roles for b 2 signaling in hippocampusdependent memory retrieval have not been described. Of potential relevance, b 1 and b 2 signaling in the prefrontal cortex have opposite effects on working memory (Ramos et al. 2005 (Ramos et al. , 2008 .
In this study, animals were tested in both Pavlovian and instrumental fear conditioning paradigms. Xamoterol and other pharmacologic reagents previously untested in these paradigms were administered to wild-type mice, as well as to mice genetically modified to lack either b 1 -or b 2 -adrenergic receptors. Our results provide substantial and unexpected evidence that signaling by G i/o -coupled b 2 -adrenergic receptors in the hippocampus mediates xamoterol-induced impairment of memory retrieval.
Results

Xamoterol impairs hippocampus-dependent memory retrieval
To confirm the impairing effects of xamoterol on hippocampusdependent memory retrieval, mice were trained using either Pavlovian or instrumental fear conditioning. When 1 -6 mg/kg of xamoterol was administered 30 min prior to testing, wild-type (WT) mice showed reduced contextual freezing and shorter avoidance latencies 1 d after training (Figs. 1A, 4A below). Because xamoterol-induced impairment of contextual freezing could be due to effects on memory or to nonspecific effects on fear or freezing, xamoterol (6 mg/kg) was also administered 30 min prior to testing cued fear 1 d after training. Xamoterol did not affect cued fear expression, indicating that it does not alter fear or freezing per se (Fig. 1B) .
Xamoterol could affect memory via receptors located in the periphery or the CNS (Gold 2004) . To distinguish between these possibilities, the peripheral nonselective b receptor antagonist nadolol (Goldaniga et al. 1980; Woods and Robinson 1981) was administered with or without xamoterol. Nadolol impairs contextual fear memory retrieval when administered centrally but not peripherally (Murchison et al. 2004 ). Nadolol did not prevent the impairment induced by xamoterol (Fig. 1C) , suggesting that xamoterol acts centrally to impair retrieval. To determine if xamoterol acts specifically in the hippocampus, cannulae were implanted in mice so that bilateral DH infusions could be performed. One week after surgery, cannulated mice were fear conditioned. One day later, either vehicle or xamoterol was infused 15 min before testing. Xamoterol decreased contextual freezing with a maximum effect at 10 mg (Fig. 1D) . As a control, xamoterol (10 mg) was infused into the DH 15 min prior to testing cued fear 1 d after training. Xamoterol did not affect cued fear expression, indicating that it does not alter fear or freezing when delivered directly into the DH (Fig. 1E) .
Although motivation and performance effects were excluded above, it remained possible that xamoterol affected contextual fear memory by impairing either retrieval itself or expression of Mice were fear conditioned and 1 d later vehicle or xamoterol was administered subcutaneously 30 min before testing contextual fear. Xamoterol caused a U-shaped, dose-dependent reduction in freezing that was maximal at 6 mg/kg. There were 5 mice per group except at 0 and 3 (11 and 10). F (5,35) ¼ 10.1 and P , 0.0001 for the main effect of dose. (B) Mice were fear conditioned and 1 d later vehicle or xamoterol (Xam) was administered subcutaneously 30 min before testing cued fear. Xamoterol did not affect freezing before (Pre-CS) or during the tone used for training (conditioned stimulus ¼ CS), indicating that xamoterol does not alter fear or freezing per se. There were 8 and 5 mice per group for vehicle and xamoterol. F (1,24) ¼ 48 and P , 0.0001 for the main effect of tone; the main effect of drug and the interaction were not significant. (C ) Xamoterol (6 mg/kg) impaired freezing when combined (X/N) with 3 mg/kg of the peripheral b receptor antagonist nadolol (Nad), indicating that xamoterol acts centrally to impair retrieval. F (1,28) ¼ 48 and P , 0.0001 for the main effect of xamoterol; the main effect of nadolol (P ¼ 0.1) and the interaction were not significant, although there was a trend for nadolol to increase freezing slightly in both groups. (D) Bilateral cannulae targeting the DH were implanted in mice. One week later, the mice were fear conditioned, and on the following day they were tested for contextual fear. DH infusions were performed 15 min before testing, with xamoterol causing impairment at 10 and 15 mg/DH. There were 5 and 6 mice per group for 0 and 10 and 5 and 15 mg/DH groups, respectively. F (3,18) ¼ 3.65 and P ¼ 0.032 for the main effect of dose. (E) Mice were fear conditioned, and 1 d later vehicle or xamoterol was infused into the DH 15 min before testing cued fear. Xamoterol did not affect freezing before or during the CS, indicating that DH infusion also does not alter fear or freezing. There were 5 mice per group. F (1,16) ¼ 269 and P , 0.0001 for the main effect of tone. ( * ¼ P , 0.05,^¼ P , 0.01, and # ¼ P , 0.001 for post-hoc comparisons.) the retrieved memory. To distinguish between these, extinction of the contextual fear memory was examined 1 d after the initial retrieval test. If xamoterol impairs retrieval 1 d after training, then testing memory again the next day (2 d after training) without further treatment should demonstrate normal contextual fear (i.e., minimal extinction). Alternatively, if xamoterol impairs expression but not retrieval, then it is predicted that testing memory again the next day should demonstrate reduced (i.e., extinguished) contextual fear. In performing similar studies examining the role of NE in retrieval and extinction, we demonstrated that it is necessary to retrieve but not express contextual fear memory for extinction to proceed (Ouyang and Thomas 2005) . When vehicle was administered shortly before testing on the day after training, freezing was high, as expected (Fig. 2) . When these mice were tested again the next day (no injection), freezing was significantly lower. In contrast, when xamoterol was administered shortly before testing on the day after training, freezing was low, as expected. When these mice were tested again the next day (no injection), freezing was significantly higher compared to the first day of testing and compared to the vehicleinjected mice on the second day of testing. The results are consistent with the idea that xamoterol impairs memory retrieval rather than memory expression.
Pharmacologic evidence that xamoterol disrupts retrieval through b 2 -and not b 1 -adrenergic signaling
The above data indicate that 0.6 mg/kg xamoterol does not impair contextual memory retrieval (Fig. 1A) . In comparison, 0.3 mg/kg xamoterol induces significant rescue of contextual memory retrieval in NE-deficient Dbh 2/2 mice (Murchison et al. 2004) . This difference could be the result of a potentially greater sensitivity to b 1 -adrenergic agonists in Dbh 2/2 mice. Alternatively, the impairment of retrieval in wild-type mice could be due to effects of xamoterol that are independent of b 1 signaling. In this regard, the most closely related receptor to b 1 is the b 2--adrenergic receptor. To test the idea that higher doses of xamoterol might stimulate b 2 in addition to b 1 receptors, a highly selective antagonist of b 2 receptors (ICI 118,551) was employed (Tsuchihashi et al. 1990 ). In agreement with previous results (Murchison et al. 2004 ), 1 mg/kg ICI 118,551 had no effect on contextual memory retrieval 1 d after training (Fig. 3A) . However, co-injection of the b 2 antagonist with xamoterol (6 mg/kg) blocked the impairment of contextual fear in a dosedependent manner, with 1 mg/kg ICI producing full rescue of retrieval (Fig. 3A) . To determine whether ICI nonspecifically elevates contextual freezing when freezing is relatively low, mice were conditioned using a less intense shock (0.35 mA), and vehicle or ICI was administered 30 min prior to testing. Contextual fear did not differ between the groups, indicating that ICI does not enhance fear or freezing per se (Fig. 3B ).
In the above experiments, the use of contextual fear testing was limited by the fact that b 1 antagonists impair contextual memory retrieval on their own. To directly compare the effects of b 1 and b 2 antagonists on the retrieval impairment induced by xamoterol, mice were subjected to instrumental fear conditioning. Similar to the results for contextual fear, 1 mg/kg ICI did not reduce retention latencies; however, it completely prevented the impairment in retrieval induced by xamoterol (Fig. 3C) . Further, the highly selective b 1 antagonist betaxolol (Tsuchihashi et al. 1990 ) at 1 mg/kg did not affect retention latencies when administered alone. In addition, betaxolol did not prevent xamoterol-induced disruption of inhibitory avoidance (Fig. 3C) , even though 1 mg/kg betaxolol is a maximally Figure 2 . Retrieval of hippocampus-dependent memory is impaired by xamoterol. Vehicle (Veh) or xamoterol (Xam, 6 mg/kg) was injected 30 min before testing 1 d after training. As expected, xamoterol impaired contextual fear memory relative to vehicle. The mice were tested again the next day without injection. Mice treated with vehicle on day 1 exhibited significantly lower freezing on day 2 compared to day 1, consistent with the extinction of contextual fear. Mice treated with xamoterol on day 1 exhibited significantly higher freezing on day 2 compared to day 1 and compared to vehicle-treated mice on day 2, indicating that extinction was minimal. Because it is not necessary to express contextual fear to obtain extinction (Ouyang and Thomas 2005) , the results suggest that xamoterol impairs retrieval rather than the expression of contextual fear. There were 5 mice for Veh and 9 mice for Xam. F (1,26) ¼ 25 and P , 0.0001 for the interaction of treatment and day; the main effects of treatment and day were not significant. ( * ¼ P , 0.05,^¼ P , 0.01, and # ¼ P , 0.001 for post-hoc comparisons.) Figure 3 . Impairment of retrieval by xamoterol is prevented by a b 2 but not a b 1 antagonist. (A) Co-injection of xamoterol (Xam, 6 mg/kg) with the b 2 antagonist ICI 118,551 (ICI) blocked xamoterol-induced impairment of contextual fear, with 1 mg/kg ICI completely preventing disruption of retrieval. ICI (1 mg/kg) alone had no effect on retrieval. There were 5 mice per group except at 0.3 mg/kg ICI (6). F (5,25) ¼ 9.4 and P , 0.0001 for the main effect of treatment. (B) ICI does not enhance low levels of contextual fear in the absence of xamoterol (P ¼ 0.9). There were 5 and 4 mice for vehicle and xamoterol. Animals were trained with lower shock intensity (0.35 mA) to approximate xamoterol-impaired freezing. (C ) Xamoterol (6 mg/kg) reduced retention latencies for inhibitory avoidance relative to vehicle. Co-administration of xamoterol with ICI (1 mg/kg) prevented xamoterol-induced disruption of avoidance, while co-injection of xamoterol with the b 1 antagonist betaxolol (Bet, 1 mg/kg) failed to prevent disruption of retrieval. Neither Bet nor ICI altered avoidance when administered alone. There were 24, 22, 12, 15, 7, and 6 mice per group from left to right. F (5,80) ¼ 5.14 and P ¼ 0.0004 for the main effect of treatment. Cold (Murchison et al. 2004 ).
Genetic evidence that xamoterol disrupts retrieval through b 2 -and not b 1 -adrenergic signaling
We sought to confirm the pharmacologic evidence suggesting that xamoterol is activating b 2 and not b 1 receptors to impair retrieval. Toward this goal, we examined the effects of xamoterol on retrieval in mice lacking either b 1 -or b 2 -adrenergic receptors. Instrumental fear conditioning was used because b 1 KOs exhibit impaired contextual memory retrieval (Murchison et al. 2004) . b 1 KO and b 2 KO mice displayed normal retention latencies when treated with saline, which allowed for the examination of drug affects (Fig. 4) . In WT mice, xamoterol significantly reduced avoidance latencies at 1 and 6 mg/kg. Importantly, xamoterol did not reduce avoidance latencies in b 2 KOs at any dose tested, indicating that b 2 signaling is necessary for the impairing effects of xamoterol on retrieval. In contrast, xamoterol at 0.3 and 1 mg/ kg impaired avoidance in b 1 KOs, indicating that b 1 signaling is not required for the disruption of retrieval by xamoterol. Interestingly, there was about a three-fold leftward shift in the U-shaped dose-response curve for xamoterol in the absence of b 1 receptors, indicating that xamoterol more potently impaired retrieval in the absence of b 1 receptors.
Pertussis toxin blocks the impairing effects of xamoterol on retrieval
Canonical b-adrenergic receptor signaling is via coupling to and activation of the adenylyl cyclase-stimulatory G protein G s . However, there is evidence that b 2 receptors can also signal through G i/o (Xiao et al. 1995; Daaka et al. 1997; Devic et al. 2001) . Because cAMP signaling is necessary and sufficient for contextual memory retrieval mediated by NE and b 1 receptors (Ouyang et al. 2008) , we asked whether b 2 signaling might oppose b 1 /G s signaling in retrieval by activating G i/o .
To test this idea, pertussis toxin (PTx) was employed because it uncouples G i/o proteins from their receptors by ADP-ribosylation. Because PTx can take several days to be fully effective in the hippocampus in vivo (Goh and Pennefather 1989; Stratton et al. 1989) , PTx was infused into the DH 1 d before fear conditioning to minimize potential effects on acquisition and consolidation. Mice were then tested 2 d after conditioning. Pretreatment with PTx did not affect retrieval in mice infused with vehicle 15 min before testing (Fig. 5) . Strikingly, however, PTx pretreatment completely prevented the impairment of retrieval induced by xamoterol.
Xamoterol impairs the retrieval of intermediate-term memory
NE, b 1 , cAMP, and PKA signaling all have time-limited roles in hippocampusdependent emotional memory retrieval (Murchison et al. 2004; Ouyang et al. 2008) . NE-deficient mice display deficits in contextual fear 0.1-4 d but not 5+ d after training, and mice and rats treated with a b receptor antagonist show compromised contextual fear and spatial navigation over a similar time course. Therefore, we determined if b 2 signaling induced by xamoterol might also have time-limited effects on retrieval. To examine short-term contextual memory, mice were injected systemically 30 min before testing and were tested at either 1 or 2 h after training. Xamoterol impaired retrieval at 2 h but not at 1 h after training (Fig. 6A) . To examine longer-term contextual memory, mice were tested at either 1, 3, or 5 d after training. Contextual fear did not differ between days 1, 3, and 5 in vehicle-injected animals (Fig. 6B) . However, the effects of xamoterol were time-sensitive, with animals displaying the greatest impairment 1 d after training, less impairment 3 d after training, and no impairment 5 d after training. Similar results for longer-term memory were obtained for inhibitory avoidance (Fig. 6C) . The results indicate that xamoterol affects an intermediate phase of memory retrieval. They also indicate that xamoterol does not impair contextual information processing or the expression of instrumental fear via mechanisms unrelated to memory retrieval.
Discussion
A role for NE and b 1 -adrenergic signaling in hippocampusdependent emotional memory retrieval is supported by multiple experimental outcomes. NE-deficient Dbh 2/2 mice exhibit impaired retrieval of contextual and spatial reference memory, and contextual memory retrieval is rescued in these mice by xamoterol ( Relevant to this, the locus coeruleus has been found to degenerate in Down syndrome (Mann et al. 1985; Marcyniuk et al. 1988) . In a mouse model of Down syndrome (Ts65Dn), there is less CNS NE, fewer locus coeruleus adrenergic neurons, and more b receptorpositive neurons in the hippocampus, suggesting the presence of functional NE deficiency (Dierssen et al. 1997; Salehi et al. 2009 ). Similar to Dbh 2/2 mice, Ts65Dn mice display deficits in contextual fear memory retrieval but not in cued fear memory, and administration of a NE precursor or xamoterol reverses the impairment of memory retrieval in Ts65Dn mice by activating central b 1 receptors (Salehi et al. 2009; Faizi et al. 2011) .
The goal of this study was to resolve the conflicting ideas that b 1 signaling is required for the retrieval of hippocampusdependent emotional memory as outlined above and is also responsible for the impaired retrieval of such memories by xamoterol (Roozendaal et al. 2004 ). In Roozendaal et al., doses of 3 and 10 mg/kg were used to demonstrate retrieval impairment. In contrast, xamoterol rescues contextual memory retrieval in NE-deficient Dbh 2/2 mice at 0.3 and 1 mg/kg. The potency of xamoterol for b 1 relative to b 2 receptors is 10-fold in rat tissue ex vivo and at mouse adrenergic receptors in vitro (Malta et al. 1985; Beer et al. 1988; Murchison et al. 2004) . As a result, we hypothesized that the higher doses of xamoterol activate b 2 as well as b 1 receptors and that the activation of b 2 receptors impairs retrieval. In the current study, we found that xamoterol impairs memory retrieval in the presence of a b 1 antagonist and in b 1 KO mice (Figs. 3C, 4B ), indicating that b 1 signaling is not required for the impairment of retrieval by xamoterol. In contrast, we found that the impairing effects of xamoterol were absent both in the presence of a b 2 antagonist and in b 2 KO mice (Figs. 3,  4C ). These results demonstrate that xamoterol impairs retrieval through the stimulation of b 2 receptors. In support of a critical role for b 2 receptors, we have also found that low doses of the b 2 receptor agonists procaterol and zinterol impair memory retrieval in mice and rats (Schutsky et al. 2011 ). The results suggest that b 2 receptors oppose the role of b 1 receptors in retrieval and provide an explanation for why relatively high doses of xamoterol are required to observe impairment, i.e., because xamoterol stimulates both receptor subtypes. Consistent with this idea, xamoterol impaired memory retrieval for inhibitory avoidance at lower doses in b 1 KO mice as compared to wild-type mice (Fig. 4) .
Classically, b-adrenergic receptors couple to the adenylyl cyclase-stimulatory G protein G s , and their activation increases cAMP levels. Given that b 1 receptors and cAMP signaling in the hippocampus are required for hippocampusdependent emotional memory retrieval (Murchison et al. 2004; Ouyang et al. 2008) , it was not apparent how activation of b 2 receptors in the hippocampus would impair retrieval. One possibility was that these two receptor subtypes are expressed on different cells or in distinct subcellular compartments, where increases in cAMP would have opposing effects on processes important for retrieval. However, a second possibility was suggested by recent studies examining signaling by b 2 receptors. Evidence suggests that b 2 receptors can couple to the pertussis toxin-sensitive, adenylyl cyclase-inhibitory G protein G i and that such coupling can limit or prevent increases in cAMP in cardiac myocytes (Xiao et al. 1995; Daaka et al. 1997; Devic et al. 2001) . In support of the relevance for such a mechanism in the brain for memory retrieval, uncoupling G i/o proteins from their receptors by PTx pretreatment of the DH blocked the impairing effect of xamoterol (Fig. 5 ) and the b 2 agonist zinterol (Schutsky et al. 2011) .
Based on the above, the simplest explanation for the impairing effects of xamoterol is that they oppose the increase in cAMP that is necessary for retrieval. This idea is consistent with the observation that xamoterol was more potent at impairing memory retrieval in b 1 KO mice as compared to wild-type mice (Fig. 4) . In other words, when both receptors are present, higher levels of b 2 stimulation are required to offset the stimulation of b 1 receptors. Highlighting the contrasting roles of these two receptors, b 2 signaling in the heart acts to protect cardiomyocytes from excessive b 1 stimulation that can lead to apoptosis and heart failure if unchecked (Rockman et al. 2002; Zheng et al. 2005 ). Further, stimulating b 2 receptors in the prefrontal cortex can enhance working memory, while stimulating b 1 receptors impairs working memory (Ramos et al. 2005 (Ramos et al. , 2008 . Other mnemonic roles for b 2 signaling that have been recently described include reconsolidation and stress-induced reinstatement of conditioned place preference for cocaine (Bernardi et al. 2009; Mantsch et al. 2010) .
Xamoterol exhibited U-shaped dose-response curves for retrieval impairment when administered systemically to wildtype and to b 1 KO mice (Figs. 1A, 4) . The reason why impairment dissipates with higher doses is not clear. The U-shaped dose-response data from b 1 KO mice rule out stimulation of b 1 receptors as an explanation. It is possible that higher levels of b 2 stimulation result in more rapid desensitization of b 2 signaling, or that the recruitment of additional signaling pathways by b 2 receptors mitigates signaling induced by lower levels of stimulation. Alternatively, xamoterol may stimulate other receptors (adrenergic or non-adrenergic) at the highest doses that counteract the effects of b 2 stimulation on retrieval.
Interestingly, our data demonstrate that the duration between acquisition and retrieval is an important factor for determining the extent of retrieval impairment (Fig. 6) . The time course for the effects of xamoterol on retrieval was essentially identical to that for the requirement of NE, b 1 , cAMP, and PKA signaling in retrieval (Murchison et al. 2004; Ouyang et al. 2008) , i.e., retrieval of an intermediate phase of memory is susceptible. (A) Xamoterol (6 mg/kg) or vehicle was administered 30 min prior to testing at 1 or 2 h after training (separate groups of mice for each time). Xamoterol impaired contextual fear at 2 h but not 1 h after training. There were 5 mice per group except vehicle at 1 h (8). F (1,21) ¼ 9.65 and P ¼ 0.006 for the interaction of treatment and time; the main effects of time and treatment were not significant. (B,C ) Xamoterol (6 mg/kg) or vehicle was administered 30 min prior to testing at 1, 3, or 5 d after training (separate groups of mice for each test day). (B) Xamoterol impaired contextual fear at 1 and 3 but not 5 d after training. There were 5 mice per group except for vehicle on day 5 (7) and xamoterol on day 3 (10). F (1,35) ¼ 44.1 and P , 0.0001 for the main effect of treatment; F (2,34) ¼ 20.7 and P , 0.0001 for the main effect of day; F (2,34) ¼ 18.8 and P , 0.0001 for the interaction. (C ) Xamoterol impaired inhibitory avoidance at 1 but not 3 or 5 d after training. There were 22, 24, 7, 8, 9 , and 7 mice per group going from left to right. F (1,43) ¼ 4.1 and P ¼ 0.05 for the main effect of treatment; F (2,42) ¼ 4.13 and P ¼ 0.024 for the main effect of day; F (2,42) ¼ 4.9 and P ¼ 0.013 for the interaction. ( * ¼ P , 0.05, ¼ P , 0.01, and # ¼ P , 0.001 for post-hoc comparisons.)
Short-term (1 h) and longer-term (5 d) memory were not affected by xamoterol. The results are consistent with the idea that different phases of memory, likely defined by various consolidation processes, can have distinct requirements for their retrieval. Further, the lack of impairment at 1 h and at 5 d indicates that xamoterol does not impair non-mnemonic emotional or sensorimotor processes. With respect to mnemonic function, the effect of xamoterol is not due to a rapid reversal of consolidation or a rapid facilitation of extinction during testing, because the contextual fear memory was expressed at high levels the following day in the absence of further treatment (Fig. 2) .
A potentially important aspect of b-adrenergic receptor physiology is that NE, the adrenergic neurotransmitter in the DH, is an order of magnitude more potent in activating b 1 receptors than b 2 receptors . As a result, it seems likely that moderately arousing conditions would facilitate hippocampus-dependent emotional memory retrieval through the release of NE and activation of b 1 receptors. Extending this idea, strongly arousing conditions typical of "stress" would impair memory retrieval through the release of additional NE and also glucocorticoids that together would activate b 2 receptors. Other studies have demonstrated that glucocorticoids impair hippocampus-dependent emotional memory retrieval (de Quervain et al. 1998 (de Quervain et al. , 2000 . Studies from our lab indicate that this effect of glucocorticoids is mediated by activation of the b 2 receptor and that NE and glucocorticoids synergize to activate this receptor at doses that are ineffective when present individually (Schutsky et al. 2011) . Because strongly arousing conditions enhance memory consolidation, this could facilitate a temporary shift away from processes favoring retrieval toward those favoring consolidation.
Materials and Methods
Subjects
Wild-type, b 1 KO, and b 2 KO mice were on a hybrid 129/Sv x C57BL/6 background and were derived by mating either heterozygotes or homozygotes (Rohrer et al. 1996; Chruscinski et al. 1999 ). Gender and parental genotype did not affect the results, so data were combined. Genotype was determined by PCR. Mice were maintained on ad lib food and water and a 12-h light:dark cycle, with lights on beginning at 07:00. Animals were housed in relatively small, quiet rooms for 3-4 wk before studies began to minimize the stress associated with caretaking and colony management during the light phase. Mice were 3 -6-mo old when tested. Studies were performed during the light phase, with most experiments taking place between 08:00-15:00. Studies were in accordance with NIH guidelines and had the approval of the IACUC at the University of Pennsylvania.
Pavlovian fear conditioning
Adjacent to the training room, animals were placed in pairs into opaque plastic holding buckets ( 12 cm diameter) with bedding and covers for 30-60 min before being manipulated further. Animals were given two 3-min handling sessions over 2 d in the training room. Saline was injected at the end of handling each day. Training consisted of placing the animal in the conditioning apparatus (ENV-010MC with ENV-414S, Med Associates) for 2 min, after which an 84 dB, 4.5 kHz tone was activated for 30 sec. Two seconds before the end of the tone, a 2-sec, 1 mA footshock was delivered. The animal was returned to its home cage 30 sec after shock, and the apparatus was cleaned with Versa-Clean (Fisher). Contextual fear was tested for 5 min in the conditioning apparatus in the absence of the tone. Cued fear was tested in a separate cohort using a Plexiglas cylinder (21-cm-diameter, 24 cm tall) with green wire grid floor and vertical green and white wall stripes 240˚around. The cylinder was located in a different area of the training room and was cleaned with lemon-scented Ajax after training each animal. After
Instrumental fear conditioning
Animals were handled as described above. Training consisted of placing a rodent in the lighted chamber of the apparatus used for Pavlovian conditioning and timing its latency to enter (except for the tail) the dark chamber. Once the animal entered the dark chamber, the retractable partition separating the two chambers was lowered, and a shock was delivered for 2 sec (0.30-0.35 mA). After waiting 15 sec, rodents were returned to their home cage, and the apparatus was cleaned. Animals that did not enter the dark chamber after 100 sec during conditioning were excluded (,4% of mice, independent of genotype). Testing was identical to training except that no shock was delivered, and the partition remained up. Latencies to enter the dark chamber were recorded. If an animal did not enter the dark chamber within 10 min, it was returned to its cage and assigned a latency of 10 min. Assigned latencies of 10 min ranged from half of the mice in some groups to no mice in other groups. Tests were conducted 1 d after training except where indicated.
Drugs
Nadolol (Sigma), betaxolol HCl, ICI 118,551 HCl, and/or xamoterol hemifumarate (Tocris) were dissolved in vehicle (0.9% saline containing 0.1 mg/mL ascorbic acid, pH 7.4, Sigma) and administered subcutaneously 30 min before testing because the behavioral effects of xamoterol are maximal with this time interval. For DH infusion, xamoterol and pertussis toxin (Tocris) were dissolved in the same vehicle. Xamoterol was infused 15 min before testing because vehicle infusion at this time does not impair retrieval. Nadolol was used at 3 mg/kg because at 1 mg/kg it mimics ICI (1 mg/kg) in the near complete blockade of peripheral b 2 receptor-mediated effects in mice (Criscuoli and Subissi 1988) .
Dorsal hippocampus infusion
A double guide cannula (C235 system, Plastics One) was implanted under pentobarbital anesthesia (72.5 mg/kg ip) using a stereotax (SAS75/EM40M, Cartesian Research). The guide was placed 21.7 mm AP and 1.5 mm bilateral for DH infusions. The guide projected 1.5 mm below the base, and the dummy cannula extended 0.5 mm below the guide. One week after surgery, bilateral infusions were made into conscious mice while gently holding the nape of the neck. The dual injection cannula extended 0.9 mm below the guide. Infusions were 1 mL/side at 0.4 mL/ min, and the injection cannula was left in place for 30 sec before the mouse was returned to its home cage. Because studies indicate that the effects of PTx are best evaluated 3 d after infusion (Goh and Pennefather 1989; Stratton et al. 1989) , PTx was infused 3 d before testing. To minimize potential effects of PTx on conditioning, training was administered the day after PTx infusion, and testing was performed 2 d after training. A pilot study indicated that 1 ng and 10 ng PTx (comparable to or lower than what has been used by others) were similarly effective. Infusion location was assessed by infusing 1 mL of 1% methylene blue after behavioral testing. Methylene blue was observed in the center of the DH in all cases, with spread reaching each hippocampal subfield but not outside the DH, except for some in the cannula track, as previously shown (Murchison et al. 2004 ). Thus, all animals were included in the current study unless blockage of the injection cannula was observed immediately after drug infusion.
